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Chromoblastomycosis is a chronic skin infection
caused by the fungus Fonsecaea pedrosoi. Exploring
the reasons underlying the chronic nature of
F. pedrosoi infection in a murine model of chromo-
blastomycosis, we find that chronicity develops
due to a lack of pattern recognition receptor (PRR)
costimulation. F. pedrosoi was recognized primarily
by C-type lectin receptors (CLRs), but not by Toll-
like receptors (TLRs), which resulted in the defective
induction of proinflammatory cytokines. Inflamma-
tory responses to F. pedrosoi could be reinstated
by TLR costimulation, but also required the CLR
Mincle and signaling via the Syk/CARD9 pathway.
Importantly, exogenously administering TLR ligands
helped clear F. pedrosoi infection in vivo. These
results demonstrate how a failure in innate recogni-
tion can result in chronic infection, highlight the
importance of coordinated PRR signaling, and
provide proof of the principle that exogenously
applied PRR agonists can be used therapeutically.
INTRODUCTION
Chromoblastomycosis is a chronic nonfatal mycosis involving
the skin and subcutaneous tissues, which is caused by a number
of melanized fungi. The disease occurs worldwide, but is
observed most frequently in tropical and subtropical regions of
Africa and Latin America (Ameen, 2009; Santos et al., 2007).
Infection is acquired by the accidental inoculation of the etiologic
agent into the subcutaneous tissues, but it usually takes
decades following inoculation before clinical symptoms develop.
The infection is characterized by erythematous papules, which
develop with varying morphology, and systemic invasion is
rare (Ameen, 2009; Santos et al., 2007). There are no standard436 Cell Host & Microbe 9, 436–443, May 19, 2011 ª2011 Elsevier Intreatments, although approaches usually include chemotherapy,
multiple surgical excisions, and/or cryosurgery with liquid
nitrogen. Furthermore, there is often a poor response to oral
antifungal drugs, and most attempts at treatment have only
a modest success rate (Ameen, 2009; Santos et al., 2007).
A number of melanized dematiaceous fungi have been associ-
ated with chromoblastomycosis, but the most common agent
causing this disease is Fonsecaea pedrosoi (Bonifaz et al.,
2001). Little is known about this fungus, its cell wall structure,
how it is recognized by the host, or the protective /nonprotective
immune responses that are triggered upon infection. Host
defense against experimental chromoblastomycosis has been
shown to rely mainly on the ingestion and elimination of fungal
cells by cells of the innate immune system, especially neutrophils
and macrophages, but there is also some evidence supporting
a requirement of CD4+, although not CD8+, T cell-mediated
immune responses (Ameen, 2009; Santos et al., 2007). Notable
features of patients with chromoblastomycosis include increased
IL-10 and low levels of IFN-g (Ameen, 2009; Santos et al., 2007).
We were interested in understanding the reasons underlying
the chronic nature of infection with F. pedrosoi and wanted to
explore the possibility that the chronicity of this infection might
stem from an inappropriate innate immune response. In this
report, we show that F. pedrosoi is recognized by C-type lectin
receptors (CLRs), but that there is a lack of sufficient costimula-
tion of the Toll-like receptors (TLRs), and that this results in
defective inflammatory responses. Excitingly, we could re-
establish this costimulatory cytokine response by exogenous
administration of TLR agonists, which could also be used to
resolve the infection in vivo.RESULTS
Establishment and Characterization of a Murine Model
of Chromoblastomycosis
To explore the reasons underlying the chronicity of chromoblas-
tomycosis, we made use of an established murine model
(Cardona-Castro and Agudelo-Flo´rez, 1999), where mice arec.
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Figure 1. Establishment of a Murine Model
of Infection with F. pedrosoi
(A) Fungal burdens in the spleen and liver (black
lines) at various time points, as indicated, following
i.p. infection with F. pedrosoi conidia. Shown for
comparison is the clearance rate of a similar dose
of C. albicans (dotted line) (Tsoni et al., 2009).
(B) Characterization of the levels of IL-10, IFN-g,
and TNF from infected spleens.
(C) Characterization of fungal burdens and cyto-
kine levels in the spleens of wild-type (WT; black
symbols) versus IL-10/ (white symbols) mice at
day 7 postinfection. See also Figure S1. Values
shown are the mean ± SEM of two pooled
experiments, except for (C), which is mean ± SD.
*p < 0.05.
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Curing Fungal Infectioninfected intraperitoneally (i.p.) with F. pedrosoi conidia, following
which the organism disseminates to the liver and spleen, where it
persists for many weeks (Figure 1A). By comparison, infection
with a pathogen causing an acute infection, such as Candida
albicans, is cleared rapidly (Tsoni et al., 2009) (dotted line in Fig-
ure 1A). Characterization of the spleens of the infected animals
revealed high levels of IL-10 as well as low levels of TNF and
IFN-g, cytokine profiles similar to those described in infected
humans (Ameen, 2009; Santos et al., 2007) (Figure 1B).
To determine whether IL-10 was contributing to the persis-
tence of the infection in our mice, we compared fungal burdens
and cytokine profiles in wild-type and IL-10-deficient animals
7 days after infection. This time point was chosen as it allowed
us to examine primarily the innate response to this pathogen
(see later). Unexpectedly, the lack of IL-10 only marginally
reduced the fungal burdens in the organs of the infected animals
and did not greatly influence the inflammatory responses to this
pathogen, as determined by measuring the levels of TNF in the
infected organs (Figures 1C and S1). Thus, these results sug-
gested that IL-10 was not a major factor involved in establishing
the chronicity of infection with F. pedrosoi.
F. pedrosoi Fails to Induce Inflammatory Responses
from Macrophages
Wenext explored the innate recognition ofF. pedrosoiby charac-
terizing its interactions with thioglycollate-elicited macrophagesCell Host & Microbe 9, 436–in vitro. We found that the conidia bound
to macrophages in a dose-dependent
fashion, yet surprisingly failed to stimulate
the production of TNF, even at high multi-
plicities of infection (moi) (Figure 2A). In
contrast, recognition of the fungal particle
zymosan,whichwas included as a control
in these experiments, induced a robust
inflammatory response, as expected
(Brown et al., 2003).
To explore the possibility that
F. pedrosoi was actively suppressing
leukocyte inflammatory responses, we
examined the interaction ofmacrophages
with heat-killed (HK) conidia. However,
despite the heat treatment, macrophagesstill failed to respond to the conidia (Figure 2B). In addition, pro-
longed coculture for 20 hr with viable conidia, during which
time the pathogen formed hyphae, similarly did not result in the
induction of TNF (data not shown). The targeting of complement
receptor 3 (CR3) is another suppressive mechanism of fungi
(Brandhorst et al., 2004); however, loss of CR3 did not restore
TNF responses to F. pedrosoi conidia (Figure 2C). Thus, the
lack of inflammatory responses toF. pedrosoiwasdue to a failure
of innate recognition andnot active suppressionby thepathogen.
Inflammatory Responses to F. pedrosoi
Can Be Reinstated by TLR Costimulation
We have previously demonstrated that the recognition of fungal
b-glucans by macrophages is not sufficient to induce inflamma-
tory responses, in the absence of additional costimulation
through MyD88-coupled TLRs (Brown et al., 2003; Dennehy
et al., 2008; Rosas et al., 2008). Thus, we next considered the
possibility that the failure of F. pedrosoi conidia to induce in-
flammatory responses was due to a lack of PRR costimulation.
We first determined whether b-glucans were exposed in
F. pedrosoi and could demonstrate that both conidial and
hyphal forms of this pathogen displayed these carbohydrates
at the cell surface (Figure 2D). Interestingly, heat killing did
not significantly alter the level of b-glucan exposure (Fig-
ure S2A). Using transfected macrophages, we could also
demonstrate that the b-glucan receptor Dectin-1 could directly443, May 19, 2011 ª2011 Elsevier Inc. 437
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Figure 2. The Response of Thioglycollate-Elicited Peritoneal Macrophages to F. pedrosoi Is Defective, but Can Be Restored Following Exog-
enous TLR Costimulation
(A) Binding of F. pedrosoi and measurement of TNF responses in macrophage culture supernatants, 3 hr after stimulation with conidia (moi 5:1 and 50:1).
(B) Binding of live and heat-killed (HK) F. pedrosoi and measurement of TNF responses in macrophage culture supernatants, 3 hr after stimulation with conidia
(MOI 5:1).
(C) Binding of F. pedrosoi and measurement of TNF responses in wild-type (WT; black bars) versus CR3/ (white bars) macrophage culture supernatants, 3 hr
after stimulation with conidia (MOI 5:1 and 50:1).
(D) Confocal image showing staining of live F. pedrosoi conidia and hyphae with soluble Fc-Dectin-1 or Fc-CLEC9A chimeric proteins. See also Figure S2A.
(E) Binding of F. pedrosoi conidia (MOI 1:1 and 1:10) to RAW264.7 cells transduced with Dectin-1 (black bars) or vector control (white bars).
(F) Costimulation of wild-type (WT; black bars) or Dectin-1/ (white bars) thioglycollate-elicitedmacrophages with Pam3CSK4, b-glucan particles, or F. pedrosoi
(MOI 5:1 and 25:1), as indicated. See also Figures S2C and S2D.
(G) Costimulation of human monocyte-derived macrophages (MF) or murine bone-marrow-derived dendritic cells (BMDCs) with F. pedrosoi (MOI 5:1),
Pam3CSK4 (10 ng/ml), LPS (1 ng/ml), or Imiquimod (1mg/ml), as indicated. See also Figure S2B. In some experiments, zymosan (zy; 25 particles per cell) was
included as a positive control. Values shown are the mean ± SD, and the data are representative of at least two independent experiments, except for the human
MF, which are mean ± SEM of pooled data from three donors. *p < 0.05.
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Curing Fungal Infectionmediate the binding of F. pedrosoi conidia to host cells
(Figure 2E).
We then explored the effect of TLR costimulation on macro-
phage inflammatory responses by making use of substimulatory
doses of the TLR2 agonist Pam3CSK4, which we had previously
shown to work synergistically with Dectin-1 (Dennehy et al.,
2008). Remarkably, while the addition of F. pedrosoi conidia to438 Cell Host & Microbe 9, 436–443, May 19, 2011 ª2011 Elsevier Inmacrophages failed to induce significant levels of TNF, as we
had observed before, costimulation with Pam3CSK4 induced
robust responses (Figure 2F). Similar results were also observed
using human peripheral blood-derivedmacrophages andmurine
bone-marrow-derived dendritic cells (BMDCs) (Figure 2G).
Furthermore, as we had previously demonstrated with purified
b-glucan (Dennehy et al., 2008), costimulation with F. pedrosoic.
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Figure 3. Characterization of the Compo-
nents Involved in the TLR/F. pedrosoi Costi-
mulatory Response
(A–E) Measurement of TNF levels in BMDC
supernatants following a 3 hr stimulation with
Pam3CSK4 or F. pedrosoi (MOI 5:1), as indicated.
Responses weremeasured in wild-type (WT; black
bars) cells versus BMDCs deficient (white bars) in
MyD88 (A), Syk (B), CARD9 (C), FcRg (D), or Mincle
(E). See also Figure S3. Values shown are the
mean ± SD, and the data are representative of at
least two independent experiments.
(F) Cartoon representation of the costimulatory
signaling pathway induced by F. pedrosoi and
exogenous TLR costimulation.
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Curing Fungal Infectioncould be achieved using multiple TLR agonists, including LPS
(TLR4) and Imiquimod (TLR7) (Figures 2G and S2B). It is notable
that the stimulation of BMDCs with F. pedrosoi alone induced
some TNF, which was expected, as stimulation of the Dectin-
1/Syk signaling pathway in dendritic cells (DCs) is known to be
sufficient for cytokine induction (Dennehy et al., 2009; Rogers
et al., 2005; Rosas et al., 2008).Thus, the inability of
F. pedrosoi to induce robust inflammatory responses was due
to a lack of costimulation of the TLR pathway.
To confirm the role of Dectin-1 in these responses, we next
assessed the costimulatory response in Dectin-1-deficient
macrophages. As shown previously (Dennehy et al., 2008), the
costimulatory response to highly purified b-glucans was ablated
in Dectin-1/ cells. Unexpectedly, Dectin-1-deficient macro-
phages displayed no alterations in their ability to induce costimu-
latory responses to F. pedrosoi conidia (Figure 2F). Furthermore,
we found that loss of Dectin-1 had no effect on the ability of
primary macrophages to bind F. pedrosoi conidia (Figure S2C),
and characterization of Dectin-1/mice revealed only marginal
effects on fungal burdens in the organs of the infected animals
(Figure S2D). Thus, Dectin-1 does not contribute to the costimu-
latory responses that were observed in vitro and plays only
a minor role during infection in vivo.
F. pedrosoi-TLR Costimulation Requires Mincle
and Signaling through the Syk/CARD9 Pathway
To determine the signaling pathways and receptors involved in
mediating the costimulatory response, we next characterizedCell Host & Microbe 9, 436–BMDCs deficient in various signaling
molecules. We first examined BMDCs
deficient in MyD88 to confirm the involve-
ment of this pathway and, as expected,
found that the coaddition of F. pedrosoi
and Pam3CSK4 failed to induce a robust
inflammatory response in these cells (Fig-
ure 3A). Interestingly, the response to
F. pedrosoi alone was also partly attenu-
ated, indicating some involvement of the
MyD88 pathway in sensing of this path-
ogen by DCs. Indeed when examined
further, we found that mice deficient in
MyD88 had enhanced fungal burdens
during infection (Figure S3A). We nextdetermined if the costimulatory response required signaling
through Syk and CARD9, as we had shown for Dectin-1
(Dennehy et al., 2008), and observed that BMDCs deficient in
Syk (Figure 3B) or CARD9 (Figure 3C) failed to induce robust
inflammatory responses in the presence of F. pedrosoi and
Pam3CSK4. The responses to F. pedrosoi alone were also atten-
uated in these cells.
To date, the only other Syk-coupled receptors that have been
implicated in fungal recognition are the CLRsMincle and Dectin-
2, and both signal through the FcRg chain (Drummond et al.,
2011). Hence, we examined the role of this signaling adaptor
and found that the costimulatory response was lost in Fcg/
BMDCs (Figure 3D). We then explored the possibility of Dectin-
2 involvement, by inhibiting this receptor with blocking mono-
clonal antibodies, but observed no effect on these responses
(Figure S3B). In contrast, we found that the costimulatory
responses were completely ablated in Mincle/ BMDCs and
that this defect was specific for the recognition of F. pedrosoi,
as Mincle/ BMDCs retained normal responses to LPS (Figures
3E and S3C). Thus, these results identify the Fcg-coupled CLR
Mincle as a major receptor involved in the innate recognition of
F. pedrosoi. A model of the proposed costimulatory pathway is
shown in Figure 3F.
TLR Costimulation Cures F. pedrosoi Infection
The failure of F. pedrosoi to induce robust inflammatory
responses provides a possible explanation for the persistence
of this pathogen, so we investigated the possibility that artificial443, May 19, 2011 ª2011 Elsevier Inc. 439
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Figure 4. Curing F. pedrosoi Infection
In Vivo by Exogenous Administration of
TLR Agonists
(A) TNF in the peritoneum of mice 3 hr after the i.p.
administration of F. pedrosoi or LPS (10 ng), as
indicated. Values shown are the mean ± SEM of
two pooled experiments.
(B) Schematic diagram of the experimental
approach, showing i.p. infection with F. pedrosoi,
followed by i.p. or i.v. injection on day 3 with
a single low dose of LPS (10 ng). The mice were
sacrificed and analyzed 4 days later (day 7).
(C) Fungal burdens and TNF levels in the spleens of
infected mice with or without LPS treatment, as
indicated. See also Figure S4A. Values shown are
the mean ± SD. *p < 0.05.
(D) Fungal burdens in the spleens of infected wild-
type (black circles) or TNF/ (white circles) mice
with or without LPS treatment, as indicated. See
also Figure S4B.
(E) Fungal burdens in the spleens of infected wild-
type (black circles) or RAG2/ (white circles) mice
with or without LPS treatment, as indicated. See
also Figure S4C.
(F) Fungal burdens in the footpads at day 7 of
untreated infected mice (black circles), i.p. LPS-
treated mice (gray circles), or mice treated daily
with a topical application of Imiquimod (IMQ)
(white circles).
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Curing Fungal Infectioncostimulation of the TLR pathway, to reinstate inflammatory
responses, would help resolve the infection in vivo. We first
determined if this was possible by administering F. pedrosoi
i.p., with or without LPS, and monitoring TNF production in the
peritoneal cavity after 3 hr. LPSwas chosen for these and subse-
quent experiments, as the effects and dosage of this TLR agonist
in vivo are well characterized and as we had shown it to be able
to costimulate inflammatory responses to F. pedrosoi in vitro
(Dennehy et al., 2008) (see Figures 2G and S2B). As shown in Fig-
ure 4A, the administration of either F. pedrosoi conidia or a low
dose of LPS induced little TNF, but when added in combination,
they induced a robust inflammatory response.
To demonstrate an effect on fungal clearance, mice were in-
fected with F. pedrosoi and the disease was allowed to establish
for 3 days, following which a single low dose of LPS was admin-
istered either i.p. or i.v., and the infection in the organs was
assessed after a further 4 days (Figure 4B). Remarkably, the
administration of a single low dose of LPS, via either route,
resulted in a near complete clearance of the pathogen from
both the spleen and liver, in comparison to the untreated animals
(Figures 4C and S4A). Furthermore, as predicted from our in vitro
analyses, the administration of LPS significantly increased the
levels of TNF in the infected organs (Figures 4C and S4A). This
induction of TNF was critical for fungal clearance, since we
found LPS to have no beneficial effect in mice deficient in this
cytokine (Figures 4D and S4B). In addition, similar effects of
LPS on fungal burdens were observed in RAG2/mice (Figures
4E and S4C).
Our results suggest that the administration of TLR agonists
may be a form of treatment for chromoblastomycosis in humans,
ideally through the topical application of these agonists to in-
fected skin. However, it is possible that TLR agonists would440 Cell Host & Microbe 9, 436–443, May 19, 2011 ª2011 Elsevier Innot be effective in treating subcutaneous infections. To explore
this, we infected mice subcutaneously with F. pedrosoi and
then treated some animals with topical applications of the
FDA-approved agonist Imiquimod, which was also capable of
inducing costimulatory activity in vitro (see Figure 2). Remark-
ably, we found that the topical application of Imiquimod
significantly reduced fungal burdens in the skin at day 7
postinfection (Figure 4F). Similar reductions in fungal burdens
were also obtained in these tissues following the i.p. administra-
tion of LPS on day 3 postinfection. Thus, we conclude that rein-
stating innate inflammatory responses to F. pedrosoi by artificial
TLR costimulation in vivo can help resolve this normally persis-
tent infection.
DISCUSSION
Very little is known about the immunology underlying chromo-
blastomycosis or the reasons for the chronicity of the disease.
In this report we demonstrate that the chronic nature of this
infection stems from inadequate innate recognition and the
subsequent failure to mount protective inflammatory responses.
This failure was not due to active suppression by F. pedrosoi, as
inflammatory responses to HK organisms were similarly defec-
tive. Furthermore, this chronicity was not due to high levels of
IL-10, as the level of infection was not greatly altered in mice
deficient in this immunosuppressive cytokine. Although
F. pedrosoi was recognized by leukocyte CLRs, particularly
Mincle, we found that this recognition was not sufficient in and
of itself to trigger protective inflammatory responses.
These findings were reminiscent of b-glucan recognition by
Dectin-1, which required costimulation of MyD88-coupled
TLRs to induce robust inflammatory responses (Dennehyc.
Cell Host & Microbe
Curing Fungal Infectionet al., 2008). Indeed, we found that costimulation of leukocytes
with purified TLR agonists induced robust inflammatory
responses to F. pedrosoi, indicating that it was the lack of
recognition by this PRR family that was responsible for the
defective innate responses. Like Dectin-1, the costimulatory
response required signaling via the Syk-CARD9 pathway, but
was triggered by the FcRg-coupled CLR Mincle. We could
demonstrate this definitively by showing that the costimulatory
responses to this organism were lost in cells deficient in any of
these signaling components. While it is likely that Mincle is
recognizing a mannose-based cell wall component (Yamasaki
et al., 2009), the identity of the ligand is unclear. It should
also be noted that unlike macrophages, the recognition of
F. pedrosoi did induce some response in DCs, even in the
absence of TLR costimulation. For other Syk-dependent
responses, such as those triggered through Dectin-1, these
cellular differences have been linked to the effects of cytokines,
such as the GM-CSF used to generate the DCs and the differ-
ential usage of CARD9, but the underlying reasons are still not
fully understood (Drummond et al., 2011). Nonetheless, as for
Dectin-1, TLR costimulation induced robust inflammatory
responses to F. pedrosoi in both cell types.
The immunostimulatory components within the cell walls of
many fungi are thought to be shielded, possibly providing an
explanation for the failure of F. pedrosoi to induce protective
responses. However, the lack of response to dead organisms
indicates that this is unlikely, as heat killing is thought to disrupt
the cell wall architecture and expose underlying PAMPs (Robin-
son et al., 2009). Although this suggests that F. pedrosoi lacks
sufficient levels of exposed TLR ligands to stimulate robust
responses, the partial ablation of TNF production in the
MyD88/ DCs does indicate the presence of some ligands for
these receptors. What the nature of these ligands may be is
unclear, as the architecture and composition of the cell wall of
F. pedrosoi is largely unknown. Furthermore, the significant
increase in fungal burdens in the MyD88-deficient mice
might also suggest some contribution of TLR recognition to the
control of this pathogen, but the interpretation of these
results are complicated by the role of MyD88 in IL-1 receptor
signaling and the importance of IL-1 signaling in antifungal
immunity.
The failure of leukocytes to induce robust inflammatory
responses to F. pedrosoi led us to test the possibility that
inducing these responses, through the exogenous administra-
tion of TLR agonists, could help resolve the infection in vivo.
Indeed, using a murine model of systemic infection, we found
that the administration of LPS, either i.v. or i.p., significantly
reduced fungal burdens in infected organs. This increased fungal
clearance was due to the enhanced inflammatory responses
triggered by the exogenous costimulation of the TLRs, as LPS
failed to have an effect in TNF/ mice. However, LPS has also
been shown to induce Mincle expression in vitro (Matsumoto
et al., 1999), therefore raising the possibility of an indirect contri-
bution of this TLR agonist in host responses.
While the systemic mouse model of chromoblastomycosis is
not an accurate representation of the human subcutaneous
infection, it is thought to be the best model for studying the
chronic nature of this disease (Cardona-Castro and Agudelo-
Flo´rez, 1999). Indeed, the systemic infection is chronic in mice,Celland the pathogen persists for many weeks in the organs of
untreated animals. Importantly, the ability of artificial TLR costi-
mulation to restore inflammatory responses and induce rapid
fungal clearance, particularly in RAG-deficient mice, clearly
demonstrates that the persistence of this fungal pathogen is
primarily due to defective innate recognition. However, chronic
infection with F. pedrosoi also leads to dysregulated adaptive
immunity (Mazo Fa´vero Gimenes et al., 2005), which was not
addressed here, and it would be interesting to examine the
effect of TLR agonist treatment on the development of these
responses during the infection.
Excitingly, these results suggest that the exogenous adminis-
tration of TLR agonists could be used to treat human patients.
Although the majority of our studies were performed using
disseminated infections, we could demonstrate that a similar
approach was also feasible in a subcutaneous infection model.
While this approach requires further optimization, we found
that the topical application of Imiquimod significantly reduced
fungal burdens in the infected tissues. Our in vitro data also
suggest that such an approach may work in humans, as human
macrophages, like their mouse counterparts, failed to induce
robust inflammatory responses to F. pedrosoi in the absence
of artificial TLR costimulation.
In conclusion, we have shown that the persistence of infection
with F. pedrosoi is due to a failure in innate recognition, stem-
ming from a lack of TLR costimulation. It is tempting to speculate
that defective PRR costimulation may underlie the development
of other chronic infections and that enhancement of inflamma-
tory responses may be responsible for the anti-infective
activities reported for many immunostimulants, such as
b-glucan. Our results also highlight the importance of coordi-
nated PRR signaling and demonstrate how exogenously applied
PRR agonists could be used to treat these types of diseases. For
chromoblastomycosis in humans, this might simply involve the
topical application of appropriate TLR ligands, such as
Imiquimod.
EXPERIMENTAL PROCEDURES
Animals
Male or female 8- to 14-week-old 129Sv, 129Sv Dectin-1/ (Taylor et al.,
2007), BALB/C, BALB/C IL-10/ (Dewals et al., 2010), C57BL/6, C57BL/6
RAG2/ (Dewals et al., 2010), C57BL/6 TNF/ (Marino et al., 1997), and
C57BL/6 Myd88/ (Fremond et al., 2004) mice were obtained from the
specific pathogen-free facility of the University of Cape Town. All animal
experimentation was performed using groups of 5–10 animals, repeated at
least once, and conformed to institutional guidelines for animal care and
welfare.
F. pedrosoi Growth Conditions and Fluorescent Labeling
F. pedrosoi ATCC 46428 was streaked onto potato dextrose agar or Sabour-
aud agar plates for isolation of individual colonies for 12 days. Colonies were
cultured in a shaking incubator for 72 hr at 30C in potato broth for in vitro
and in vivo assays. The conidia were filtered to remove hyphae and washed
with PBS before use (live conidia) or were heat killed by boiling for 30 min.
For fluorescence labeling, washed live or HK conidia were labeled with
Rhodamine Green-X (Invitrogen) (200 mg/ml) for 30 min at 25C, followed by
extensive washing. To detect surface-exposed b-glucans, washed live or HK
F. pedrosoi cells were stained with soluble Fc-Dectin-1(Graham et al., 2006)
or Fc-CLEC9A (Huysamen et al., 2008) chimeric proteins (5 mg/ml), as
described previously (Graham et al., 2006). In some experiments, soluble
b-glucan (100 mg/ml) was mixed with Fc-Dectin-1 for 30 min prior to staining.Host & Microbe 9, 436–443, May 19, 2011 ª2011 Elsevier Inc. 441
Cell Host & Microbe
Curing Fungal InfectionCells and In Vitro Fungal Stimulations
DCs were generated from Syk/ fetal livers, as described (Rogers et al.,
2005), or from the bone marrow of CARD9/ (Gross et al., 2009), FcRg/
(Takai et al., 1994), Mincle/ (Yamasaki et al., 2009), MyD88, and C57BL/6
mice, using standard protocols. Human monocyte-derived macrophages
and thioglycollate-elicited macrophages were generated as described
previously (Dennehy et al., 2008; Willment et al., 2003). Macrophages and
BMDCs were plated the night before use in 24-well plates at a density of
2.5 3 105 cells per well in RPMI medium with 10% heat-inactivated FCS.
The RAW264.7 macrophages expressing Dectin-1 (Brown et al., 2002) and
control cells were plated at 2.5 3 105 cells per well in medium containing
0.4 mg/ml G418 (Invitrogen).
For the in vitro binding and cytokine assays, unlabeled or RhodamineGreen-
X-labeled live or HK F. pedrosoi were added to the cells, as indicated, and
incubated for 30 min at 37C. In some experiments, the following compounds
were also added alone or in combination, as indicated: unlabeled or
FITC-labeled zymosan (25 particles per cell) (Invitrogen), purified b-glucan
particles (100 mg/ml) (Dennehy et al., 2008), Pam3CSK4 (10 ng/ml) (Invivogen),
LPS (1 ng/ml) (Sigma), and Imiquimod (1 mg/ml) (Invivogen). Unbound particles
were removed by washing. The medium was replaced, and the cells were
cultured for a further 3 hr for analysis of TNF by ELISA (BD Biosciences).
Cytokine stimulations were not influenced by the presence or absence of
a fluorescent label on the fungal particles (data not shown). After incubation,
supernatants were stored at 80C until use, cells were lysed in 3%
(volume/volume) Triton X-100, and fluorescence was measured with a Titertek
Fluoroskan II (Labsystems).
In Vivo Models
For in vivo infections, micewere infectedwith 23 106 conidia of F. pedrosoi i.p.
In some experiments, LPS (10 ng) (Sigma) was also administered tomice i.p. or
i.v., 3 days after infection with F. pedrosoi. At appropriate time points after
infection, as indicated in the text, the animals were sacrificed, and colony-
forming units were determined in disaggregated whole livers and spleens by
serial dilution onto Sabouraud agar plates. Organ cytokine levels were deter-
mined by ELISA (BD Biosciences). To measure peritoneal inflammation, mice
were injected i.p. with 23 106 live F. pedrosoi and/or LPS (10 ng/ml) and were
killed after 3 hr. TNF was measured in peritoneal lavage fluid by ELISA (BD
Biosciences). For infection of the footpad, mice were subcutaneously injected
with 1 3 107 F. pedrosoi conidia, and then 5% Imiquimod cream (Aldara,
Graceway Phamaceuticals) was topically applied daily to the site of infection,
where indicated. In other mice, 100 ng of LPS was administered i.p. at day 3
after infection. All mice were sacrificed at day 7, and colony-forming units
were determined in disaggregated footpads by serial dilution onto Sabouraud
agar plates.
Statistics
Student’s t test was used for the analysis of two groups. Results were consid-
ered statistically significant with p values of% 0.05.
SUPPLEMENTAL INFORMATION
Supplemental information includes four figures and can be found with this
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